SCPH Stock Overview
A pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
scPharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.36 |
| 52 Week High | US$6.71 |
| 52 Week Low | US$3.08 |
| Beta | 0.14 |
| 11 Month Change | -23.98% |
| 3 Month Change | -34.63% |
| 1 Year Change | -38.80% |
| 33 Year Change | -29.71% |
| 5 Year Change | -21.13% |
| Change since IPO | -76.17% |
Recent News & Updates
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
Nov 19
Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term
Nov 18Recent updates
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
Nov 19Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term
Nov 18Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?
Jun 27scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable
Jun 27The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts
Mar 16Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?
Nov 25scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients
Oct 20FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure
Oct 10Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?
Jan 11Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?
Sep 02scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX
Aug 26Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like
Mar 09How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?
Nov 24
Shareholder Returns
| SCPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -14.1% | -3.8% | -1.0% |
| 1Y | -38.8% | 9.8% | 30.3% |
Return vs Industry: SCPH underperformed the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: SCPH underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| SCPH volatility | |
|---|---|
| SCPH Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SCPH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SCPH's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 136 | John Tucker | www.scpharmaceuticals.com |
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company’s product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector.
scPharmaceuticals Inc. Fundamentals Summary
| SCPH fundamental statistics | |
|---|---|
| Market cap | US$176.14m |
| Earnings (TTM) | -US$80.11m |
| Revenue (TTM) | US$30.28m |
5.6x
P/S Ratio-2.1x
P/E RatioIs SCPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCPH income statement (TTM) | |
|---|---|
| Revenue | US$30.28m |
| Cost of Revenue | US$9.17m |
| Gross Profit | US$21.11m |
| Other Expenses | US$101.22m |
| Earnings | -US$80.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.60 |
| Gross Margin | 69.72% |
| Net Profit Margin | -264.60% |
| Debt/Equity Ratio | 166.4% |
How did SCPH perform over the long term?
See historical performance and comparison